The latest biotech news

News and Trends 27 Apr 2023

Australian biopharma Telix banks on AI with Dedicaid acquisition

Australian biopharma company Telix Pharmaceuticals Limited is expanding its artificial intelligence (AI) capability with the signing of an agreement to acquire Austria-based Dedicaid GmbH, a spin-off of the Medical University Vienna. Dedicaid’s core asset is a clinical decision support software (CDSS) AI platform capable of rapidly generating indication-specific CDSS applications from available datasets, for use […]

April 27, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 27 Apr 2023

Vedanta Biosciences raises $106.5M for microbiome therapy

Vedanta Biosciences, a clinical-stage company developing a potential new category of oral therapies based on defined bacterial consortia, has raised $106.5 million. The funds will support pivotal-stage development of the U.S. company’s lead candidate, VE303, for the prevention of recurrent Clostridioides difficile infection (CDI), and a phase 2 study of VE202 for ulcerative colitis, among […]

April 27, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 27 Apr 2023

Patients with asthma and other inflammatory lung diseases can be treated ‘in a fundamentally new way’

Arrowhead Pharmaceuticals Inc. has announced interim results from an ongoing phase 1/2 clinical study of ARO-RAGE, an investigational RNA interference (RNAi) therapeutic designed to reduce production of the receptor for advanced glycation end products (RAGE) as a potential treatment for inflammatory pulmonary diseases, such as asthma. These data represent the first clinical demonstration of the […]

April 27, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 27 Apr 2023

Biogen ALS drug gets FDA ok

The U.S. Food and Drug Administration (FDA) has approved Biogen’s QALSODY (tofersen) 100 mg/15mL injection for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. This indication is approved under accelerated approval based on reduction in plasma neurofilament light chain (NfL) observed in patients […]

April 27, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 26 Apr 2023

LincRNA discovery could lead to targeted treatments

Our genetic code includes more than 15,000 specific sections that can be made into molecules called lincRNAs. Some of these sections can occur in coiled-up sections of our genome called topologically associating domains, or TADs. LincRNAs derived from TADs appear to act as markers indicating the specific kind of tissue they are within. When something […]

April 26, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 26 Apr 2023

Progress in battle against stomach cancer

Researchers at Ludwig-Maximilians-Universität München (LMU) in Germany have discovered a weakness in the bacterium Helicobacter pylori, which could be exploited to develop new drugs.H. pylori, a pathogen responsible for widespread illnesses such as gastric ulcers and stomach cancer, has a weak point, which could be exploited to create new drugs. This was discovered by a […]

April 26, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 26 Apr 2023

aVaxziPen’s needle-free vaccine yields positive data across multiple diseases

aVaxziPen, a biotech company developing a novel needle-free vaccine delivery platform, presented data at the World Vaccine Congress (WVC) in Washington, U.S., recently. The company presented a poster entitled, “Needle-free, injectable solid dose vaccine delivery generates equivalent immune response with different antigens and animal models.” The company said immunogenicity data from four in vivo models […]

April 26, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 26 Apr 2023

Global partners announce The Big Catch-up vaccination effort

WHO, UNICEF, Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation, along with Immunization Agenda 2030 and many other global and national health partners, are joining forces to call for “The Big Catch-up,” a targeted global effort to boost vaccination among children following declines driven by the COVID-19 pandemic. Gavi, the Vaccine Alliance, […]

April 26, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 26 Apr 2023

20Med Therapeutics and Touchlight collaborating on novel vaccine delivery platform

20Med Therapeutics, a company working on non-viral delivery and development of gene therapies and vaccines, and Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, have announced that both parties will collaborate on establishing a novel vaccination platform that combines Touchlight’s rapid enzymatic doggybone DNA platform with 20Med Therapeutics’ bioresponsive […]

April 26, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 25 Apr 2023

Gene therapy and chemotherapy could be new osteosarcoma treatment option

New research has identified a potential therapeutic target and developed a unique delivery system to treat osteosarcoma, a bone cancer that primarily affects children and adolescents. The standard-of-care treatment plan for osteosarcoma today is no different to when first introduced almost 50 years ago. However, nearly one third of patients’ relapse and need new interventions. […]

April 25, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 24 Apr 2023

LifeArc launches £40M funding call to create Translational Rare Disease Centres

LifeArc is inviting applications from academic institutions for its latest £40 million ($49.8 million) initiative to fund four or five new Translational Rare Disease Centres in the U.K., along with a separate co-ordinating hub. LifeArc, which is a self-funded, non-profit medical research charity, specializes in early-stage translation – the advancement of scientific discoveries towards patient […]

April 24, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 24 Apr 2023

RNA-based nanodrugs cause cancer cells to collapse – 80% survival rate for ovarian cancer in lab models

Researchers from Tel Aviv University in Israel have revealed details of a new approach to the treatment of ovarian cancer using RNA-based nanodrugs – demonstrating an 80% survival rate in lab models.In a study at Tel Aviv University, the protein CKAP5 (cytoskeleton-associated protein) was used for the first time as a therapeutic target for RNA-based […]

April 24, 2023 - 4 minutesmins - By Jim Cornall

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Australian biopharma Telix banks on AI with Dedicaid acquisition

Vedanta Biosciences raises $106.5M for microbiome therapy

Patients with asthma and other inflammatory lung diseases can be treated ‘in a fundamentally new way’

Biogen ALS drug gets FDA ok

LincRNA discovery could lead to targeted treatments

Progress in battle against stomach cancer

aVaxziPen’s needle-free vaccine yields positive data across multiple diseases

Global partners announce The Big Catch-up vaccination effort

20Med Therapeutics and Touchlight collaborating on novel vaccine delivery platform

Gene therapy and chemotherapy could be new osteosarcoma treatment option

LifeArc launches £40M funding call to create Translational Rare Disease Centres

RNA-based nanodrugs cause cancer cells to collapse – 80% survival rate for ovarian cancer in lab models

Subscribe to our newsletter to get the latest biotech news!